2012-08-13 21:07:53 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

This report covers antihypertensives, antidyslipidemics, and antithrombotics, which are the three leading categories of cardiovascular therapies by sales. Current and forecast sales of leading established brands in these categories are provided. Growth brands, key drug classes, and leading players through to 2017 are identified. Major pipeline products are profiled including estimated filing year.

Scope
* Identify growth brands, key drug classes, and leading players through to 2017.
* Review sales forecasts to 2017 for leading products, with analysis of key growth drivers and resistors across the seven major pharmaceutical markets.
* Evaluate the commercial impact of recently completed and ongoing clinical trials.
* Assess the target populations, market potential, and forecast approval dates of major pipeline products.
* Understand the present

unmet needs, treatment guidelines, and the epidemiology of cardiovascular disease.


Full Report Details at
- www.fastmr.com/prod/449030_the_cardiovascular_market_outlook_to_ ..


Highlights

Antihypertensives are the largest drug category within the cardiovascular market by sales, but this category will undergo significant value erosion by 2017, principally due to increasing generic competition in the angiotensin receptor blockers class, which accounted for 70% of total antihypertensive sales in 2011

The value of the antidyslipidemic class will fall to around $8.2bn in 2017, partly due to the loss of exclusivity of Lipitor, previously the world's best-selling drug. The availability of generic atorvastatin will halt Crestor sales growth up to loss of exclusivity.

Novel oral anticoagulants are likely to be the fastest growing class of antithrombotics over the forecast period, driven by sales of Boehringer Ingelheim's Pradaxa, Bayer's Xarelto, and Pfizer/Bristol-Myers Squibb's Eliquis.

Reasons to Get this Report

* How does the market outlook vary for the antihypertensives, antidyslipidemics, and antithrombotics categories up to 2017?
* What are the key growth brands?
* Which were the most important companies in the cardiovascular market in 2011?
* How will the loss of exclusivity of leading brands shape the cardiovascular market, and can pipeline products compensate for these lost sales?
* Which novel therapeutics offer significant potential for future growth?

Partial Table of Contents:

About the author

* Disclaimer

EXECUTIVE SUMMARY

* Overview and epidemiology of cardiovascular disorders
* Global market analysis
* Pipeline analysis
* Competitive landscape

Overview and epidemiology of cardiovascular diseases

* Summary
* Introduction
* Hypertension

* Diagnosis, treatment, and management
* Epidemiology

* Dyslipidemias

* Diagnosis, treatment, and management
* Epidemiology

* Stroke

* Diagnosis, treatment, and management
* Epidemiology

* Coronary heart disease
* Heart failure

Global market analysis

* Summary
* Introduction
* Key events in the cardiovascular market

* Pfizer's "house generic" Lipitor strategy attempts to preserve revenues
* Tekturna's blockbuster status in doubt following safety concerns
* Crestor no better than Lipitor in regressing coronary atherosclerosis
* AIM-HIGH trial results suggest raising HDL-C levels has no clinical benefit
* Abbott's Trilipix increases the risk of adverse cardiac events in women
* Vytorin fails to gain CKD indication and FDA adds 80mg simvastatin dose warning

* Market analysis by leading categories and brands
* Market analysis by geography
* Antihypertensives

* Introduction
* Antihypertensive drug classes
* Treatment guidelines
* Leading brands by drug class
* Key brand analysis

* Antidyslipidemics

* Introduction
* Antidyslipidemic drug classes
* Leading brands by drug class
* Key brand analysis

* Antithrombotics

* Introduction
* Antithrombotics drug classes
* Leading brands by drug class
* Key brand analysis

Pipeline analysis

* Summary
* Introduction
* Key pipeline events

* Mesoblast's stem cell therapy appears to be safe with promising signals of efficacy
* Eli Lilly's CETP inhibitor evacetrapib reports encouraging Phase II results
* Sanofi's anti-PCSK9 enters Phase III development
* Genentech/BioInvent start GLACIER trial to reduce atherosclerotic plaque

* Cardiovascular pipeline overview

* HDL-C-raising therapies
* Severe hypercholesterolemia
* Atherosclerosis
* Heart failure

Competitive landscape

* Summary
* Introduction
* Competitive positioning of top companies
* Pfizer

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

* AstraZeneca

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

* Bristol-Myers Squibb

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

* Sanofi

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

* Novartis

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

* Merck

* Overview
* Marketed product portfolio
* R&D pipeline analysis
* Strategic and growth analysis

Appendix

*

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=449030&dt=t

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.